Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 3/20 | 0.41 |
| ▸ | NQO2 | P16083 | 3/20 | 0.41 |
| ▸ | IDH1 | O75874 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | DAO | P14920 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 6/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.38 |
| ▸ | XBP1 | P17861 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3286114 | 0.70 | CA1 (0.52) | CA1CA2CA7CA9MAPT | |
| SCHEMBL9499742 | 0.68 | DAO (0.51) | CYP19A1NQO2IDH1CA1CA2 | |
| SCHEMBL20593880 | 0.67 | HAAO (0.50) | KDM4EALDH1A1ALOX15HPGDHSD17B10 | |
| SCHEMBL17885904 | 0.63 | CA12 (0.43) | CA1CA2CA7CA9DAO | |
| SCHEMBL29131019 | 0.62 | CYP19A1 (0.44) | CYP19A1NQO2DAOMAPTKDM4E | |
| SCHEMBL14438070 | 0.62 | CYP19A1 (0.61) | CYP19A1NQO2MAPTKDM4EALDH1A1 | |
| SCHEMBL3278153 | 0.62 | ALDH1A1 (0.60) | MAPTKDM4EKMT2AALDH1A1POLB | |
| SCHEMBL1635785 | 0.60 | ACHE (0.52) | CA1CA2CA7CA9MAPT | |
| SCHEMBL29793327 | 0.60 | ACHE (0.52) | CA1CA2CA7CA9MAPT | |
| SCHEMBL11134106 | 0.59 | MAPT (0.73) | CA1CA2CA7CA9MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12365945-B2 | Urinary microbiomic profiling | Convergent Genomics, Inc. (US) | 2025-07-22 | — | — | US | claimed |
| US-20250009891-A1 | CONJUGATES OF MONOCYCLIC BETA-LACTAMS AND SIDEROPHORE MIMETICS | UNIVERSITY OF NOTRE DAME DU LAC | 2025-01-09 | — | — | US | claimed |
| EP-0138420-B1 | PHARMACEUTICAL COMPOSITIONS CONTAINING 1-HYDROXYPYRID-2-ONE DERIVATIVES | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1989-11-29 | — | — | EP | claimed |
| US-20250305052-A1 | URINARY MICROBIOMIC PROFILING | Convergent Genomics, Inc. | 2025-10-02 | — | — | US | disclosed |
| US-12365945-B2 | Urinary microbiomic profiling | Convergent Genomics, Inc. (US) | 2025-07-22 | — | — | US | disclosed |
| US-12344897-B2 | Urinary microbiomic profiling | Convergent Genomics, Inc. (US) | 2025-07-01 | — | — | US | disclosed |
| US-20250009891-A1 | CONJUGATES OF MONOCYCLIC BETA-LACTAMS AND SIDEROPHORE MIMETICS | UNIVERSITY OF NOTRE DAME DU LAC | 2025-01-09 | — | — | US | disclosed |
| US-12098364-B2 | Methods and compositions for collection and preservation of biologicals | Convergent Genomics, Inc. (US) | 2024-09-24 | — | — | US | disclosed |
| EP-3606325-B1 | RATIONAL DESIGN OF MICROBIAL-BASED BIOTHERAPEUTICS | GUSTO GLOBAL LLC (US) | 2024-09-04 | — | — | EP | disclosed |
| US-20240254558-A1 | URINARY MICROBIOMIC PROFILING | Convergent Genomics, Inc. | 2024-08-01 | — | — | US | disclosed |
| EP-4405342-A2 | CYCLIC PEROXIDES AS PRODRUGS FOR SELECTIVE DELIVERY OF AGENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-07-31 | — | — | EP | disclosed |
| US-9944925-B2 | Processes and host cells for genome, pathway, and biomolecular engineering | ENEVOLV, INC. | 2018-04-17 | — | — | US | disclosed |
| US-20160186168-A1 | PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING | ENEVOLV, INC. | 2016-06-30 | — | — | US | disclosed |
| EP-3027754-A1 | PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING | enEvolv, Inc. (US) | 2016-06-08 | — | — | EP | disclosed |
| WO-2015017866-A1 | PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING | ENEVOLV, INC. (US) | 2015-02-05 | — | — | WO | disclosed |
| EP-2074240-A2 | METHOD OF INHIBITING CORROSION IN STORAGE AND TRANSPORT VESSELS | Nalco Company (US) | 2009-07-01 | — | — | EP | disclosed |
| WO-2008060782-A2 | METHOD OF INHIBITING CORROSION IN STORAGE AND TRANSPORT VESSELS | NALCO COMPANY (US) | 2008-05-22 | — | — | WO | disclosed |
| US-20080083435-A1 | METHOD OF INHIBITING CORROSION IN STORAGE AND TRANSPORT VESSELS | ECOLAB USA INC. | 2008-04-10 | — | — | US | disclosed |
| EP-0138421-B1 | HYDROXYPYRIDONE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1990-12-05 | — | — | EP | disclosed |
| EP-0138420-B1 | PHARMACEUTICAL COMPOSITIONS CONTAINING 1-HYDROXYPYRID-2-ONE DERIVATIVES | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1989-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250009891-A1 | CONJUGATES OF MONOCYCLIC BETA-LACTAMS AND SIDEROPHORE MIMETICS | MGAM, OPRM1, BPGM | CYP19A1 1315/4885NQO2 1891/4885IDH1 527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.